Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
1. Journavx launched successfully, gaining strong early traction in the market. 2. Near 90% shelf availability suggest widespread pharmacy access for Journavx. 3. Vertex's 2025 revenue projected at $11.75 to $12 billion, driven by cystic fibrosis. 4. Potential revenue boost seen from rapid adoption of Journavx and gene therapy. 5. International issues in Russia may affect Vertex's revenue growth.